I. Ford

ULCERATIONS: A SYSTEMATIC REVIEW

Leslie, Stephen, Angus, 2016 .

Cardiovascular safety of febuxostat – Authors' reply

G. Nuki, I. Mackenzie, M. Robertson, 2021, The Lancet.

Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors

J. Danesh, Jane Green, T. Peakman, 2017, The Lancet.

WOSCOPS. AUTHORS' REPLY

S. Cobbe, C. Isles, T. Barringer, 1997 .

Impact of deprivation on cardiovascular risk factors in people with diabetes: an observational study

S. Wild, I. Ford, A. McConnachie, 2008, Diabetic medicine : a journal of the British Diabetic Association.

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial

A. Doney, C. Hawkey, A. Avery, 2022, The Lancet.

Unanswered questions from the IRONMAN trial – Authors' reply

P. Kalra, I. Ford, 2023, The Lancet.

INTERPRETATION OF THROMBOSIS PREVENTION TRIAL. AUTHORS' REPLY

T. Fahey, L. Iacoviello, P. Brennan, 1998 .